Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Year in Review

Year ended March 2023

Key Figures

Net Sales
¥1,062.1billion
4.8%
Operating Income
¥75.4billion
18.8%
Operating Income Ratio
7.1%
2.1percentage points
ROE
10.0%
3.5percentage points
Capital Expenditures
¥72.1billion
R&D Expenses
¥30.9billion

Breakdown by Segment

  • Food
  • Pharmaceuticals

Net Sales

Operating Income

Business Performance Analysis

Food
Net Sales
¥865.6billion
4.8%
Operating Income
¥55.8billion
26.5%
Income Analysis(Billions of yen)
Pharmaceuticals
Net Sales
¥197.2billion
4.9%
Operating Income
¥21.7billion
16.4%
Income Analysis(Billions of yen)

Capital Expenditures

  • Food
  • Pharmaceuticals

Food

¥63.4billion

Pharmaceuticals

¥8.5billion

Cash Dividends per Share / Dividend Payout Ratio

  • Cash Dividends per Share
  • Dividend Payout Ratio

Future Prospects

This is our Medium-term Business Plan,
FYE 3/2022 through FYE 3/2024.

FYE3/2022
Results
FYE3/2023
Results
FYE3/2024
Plan
FYE3/2024
Targets
(Initial plan)
Net sales ¥1,013.0 biliion ¥1,062.1 biliion ¥1,102.0 biliion ¥1,080.0 biliion
Operating income ¥92.9 billion ¥75.4 billion ¥78.0 billion ¥120.0 billion
Operating income ratio 9.2% 7.1% 7.1% 11.1%
ROE 13.5% 10.0% 7.0% 11.0%
as of May 11, 2023 as of May 18, 2021

The Accounting Standard for Revenue Recognition is applied from FYE 3/2022. As such, the above figures are calculted based on assumption of accounting treatment changes related to revenue recognition.